A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
Latest Information Update: 03 Sep 2026
At a glance
- Drugs Guselkumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms STAR
- Sponsors Janssen Research & Development; Janssen-Cilag
Most Recent Events
- 28 Aug 2026 Planned primary completion date changed from 4 Aug 2026 to 1 Apr 2027.
- 13 Apr 2026 Status changed from recruiting to active, no longer recruiting.
- 27 Mar 2026 This trial has been completed in Denmark, Portugal, Germany, Sweden and Italy.